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Abstract 
 
Lung transplantation is the treatment of choice for end-stage pulmonary diseases.  A 
limited donor supply has resulted in 4000 patients on the waiting list. Currently, 10-20% 
of donor organs offered for transplantation are deemed suitable under the selection 
criteria, of which 15-25% fails due to primary graft dysfunction (PGD).  This has resulted 
in increased efforts to search for alternative donor lungs selection criteria. In this study, 
we attempt to further our understanding of PGD by observing the changes in gene 
expression across donor lungs that developed PGD versus those that did not. Our second 
goal is to use a machine learning tool - support vector machine (SVM), to distinguish 
unsuitable donor lungs from suitable donor lungs, based on the gene expression data. 
From our analysis, we have obtained transcripts that were involved in signalling, 
apoptosis and stress-activated pathways.  Results also indicate that metallothionein 3 may 
prevent lungs from developing PGD.  Preliminary classification results for distinguishing 
suitable and unsuitable lungs for transplantation using a SVM were promising. This is the 
first such attempt to use human lungs used for transplantation and combine the 
identification of a molecular signature for PGD, with machine learning methods for 
donor lung prediction. 
     
Introduction 
 
Lung transplantation has gained widespread acceptance for the treatment of end-stage 
pulmonary diseases. However, two significant problems in clinical lung transplantation 
are a major shortage of donor organs and the incidence of primary graft dysfunction 
(PGD).  PGD is a severe allograft ischemia-reperfusion (I/R) injury syndrome occurring 
in the hours following transplantation. It significantly affects morbidity as well as early 
and late mortality. Improvements in operative techniques, donor lungs management, and 
immunosuppressive protocols have decreased perioperative mortality to below 10% at 
most experienced lung transplant centres (1, 2).  The one- and five-year survival rates 
have improved to 76% and 49%, respectively (1). These results, however, continue to lag 
behind those achieved for other solid organ transplants.  The occurrence of PGD after 
lung transplantation significantly increases the duration of mechanical ventilation, 
hospital length of stay and short-term mortality after lung transplantation (3). Survivors 
of PGD have a significantly protracted recovery with impaired physical function up to 
one year after transplantation and an increased risk of death extending beyond the first 
year after transplantation (3, 4). 
 
The current criteria used to evaluate potential donor lungs appear to be inadequate at 
predicting how these lungs will function post-transplantation (5, 6, 7).  Donor organs are 
evaluated for lung transplantation on the basis of criteria that are primarily historically 
founded and largely arbitrary (8).  Relatively crude measures of lung function such as 
chest radiography, arterial oxygen tension in blood gases, and bronchoscopy are currently 
used to assess the quality of potential donor lungs.  That these tools are inadequate in 
evaluating organs from prospective donors is evidenced by two recent developments.  
First, the liberalisation of the selection criteria and the use of ‘marginal’ donor lungs by 
many centres have not had a negative impact on outcome after transplantation (9-11).  A 
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recent study showed no significant difference in a number of indices for infection and 
inflammation between donor lungs that were accepted and rejected for transplantation 
(7).  Second, the incidence of PGD or I/R injury, after transplantation remains unchanged 
at 15-25% despite the increased use of marginal donor lungs and improvements in all 
areas of lung transplantation (2, 4, 12).   
These issues have led investigators to search for criteria that may subject lungs to 
increased risk of PGD.  While recent studies have identified donor age and recipient 
diagnosis of primary pulmonary hypertension (PPH) as risk factors for the development 
of PGD, the aetiology of PGD in most cases after transplantation is unknown and thought 
to be due to complex interactions between donor lung and recipient immune system (13, 
14). 
  
A limited donor supply has dramatically increased the waiting time for transplant 
recipients. Approximately 4,000 patients are currently on the transplant waiting list and 
this has resulted in intense pressure to search for alternative strategies.  Unfortunately, up 
to 10-20% of these patients on the waiting list will die from their underlying lung disease 
before an organ becomes available.  Currently, only 10-20% of cadaveric donor organs 
offered for transplantation are judged to be acceptable under the current selection criteria 
(15).   More biologically meaningful donor lungs selection criteria may result in 
significant expansion of the number of lungs accepted from this potential donor pool (5). 
 
The results of the above mentioned studies suggest that there may be complex, occult 
biological factors present in donor lungs which contribute to the development of PGD 
that are not detected by the current donor organ evaluation. Gene expression profiling is a 
powerful, high-performance tool of molecular biology that allows the analysis of the 
levels of expression of thousands of genes simultaneously.  It has been previously used to 
study gene transcripts involved in I/R injury using a rat model (16).  To the best of our 
knowledge, however, this is the first report where gene expression profiling has been 
used on actual human lungs used for transplantation, along with the application of 
machine learning techniques to attempt to distinguish unsuitable donor lungs from 
suitable donor lungs. 
 
Our objective is two fold - the first is to obtain a set of genes involved in PGD and 
identify new gene products relevant to allograft transplantation; and the second is to use 
this set of genes for classification of donor lungs into PGD positive (i.e. lungs that 
develop PGD) or PGD negative (i.e. lungs that do not develop PGD) categories.  The first 
objective would provide greater insights into the mechanisms of PGD as well as extend 
the work of Yamane et al (16).  The set of genes identified as being involved in PGD can 
be designated as the ‘molecular signature’ of PGD. As many donor lungs that may be 
actually suitable for transplantation, are discarded by the current selection criteria, it 
would be useful to classify unseen donor lungs, using the molecular signature derived in 
the first objective coupled with machine learning techniques.  Such a classification can 
ultimately perhaps increase the potential donor pool for lung transplantation and is the 
motivation behind our second objective. 
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Materials and Methods 
 
Donor lung sampling 
 
From August 2003 to January 2005, 80 transplants were performed in our programme at 
Washington University School of Medicine.  Three of these were excluded from the 
study as one was a single lung transplant, another was a heart-lung transplant, and the 
third was a combined coronary artery bypass graft with lung transplant.  This resulted in 
biopsies of 77 donor lungs used for bilateral sequential lung transplantation.  The biopsies 
were obtained from the anterior right middle lobe or lingula immediately prior to cold-
flushing.  Of these 77, 9 patients did not give consent.  Of the remaining biopsies, some 
samples were excluded due to technical errors or complexities during expression 
profiling, resulting in a net total of 50 biopsies being used for the study.  Five lungs were 
considered marginal donor lungs based on them portraying one or more of the following 
conditions - either PaO2 in arterial blood gas < 300 on 100% inspired oxygen, or smoking 
history > 20 pack-years or donor age > 55.  These samples were immediately snap-frozen 
in liquid nitrogen and then stored in a -70° Celsius freezer until used for analysis.  
Specimens were sampled using standard techniques for open lung wedge biopsy.  An area 
of lung tissue approximately 1 x 1 cm was isolated and excised using 2 staple lines from 
a 30 mm EndoGIA stapler (US Surgical, Norwalk, CT).  This protocol was approved by 
the Human Studies Committee and Institutional Review Board at Washington University 
School of Medicine and protection of human subjects, namely recipients, was afforded by 
detailed informed consent before entrance into this research protocol.  No complications 
related to sampling of the donor lungs occurred in this study.  As this is a pilot study done 
on actual human lungs used for transplantation, we did not have enough tissue to perform 
RT-PCR.  
 
RNA Isolation 
 
Single isolates of donor lung samples were homogenised in the presence of RNAzolB 
and finally dissolved in RNase-free H2O.  25 g of total RNA was treated with DNase 
using the Qiagen RNase-free DNase kit and samples were further purified using RNeasy 
spin columns (Qiagen, Valencia, CA).  Total RNA treated with DNase was dissolved in 
RNase-free H2O to a final concentration of 0.2 g/l.  RNA quality was assessed by 1% 
agarose gel electrophoresis in the presence of ethidium bromide.  Samples that did not 
reveal intact and approximately equal 18S and 28S ribosomal bands were excluded from 
further study. 
 
cDNA Synthesis and Gene Expression Profiling 
 
This study used commercially available high-density microarrays (Affymetrix, Santa 
Clara, CA) that produce gene expression levels on 22,278 probe sets (Affymetrix Human 
Genome U133Av2.0 Array).  Each donor lung biopsy was analysed on a different 
GeneChip. Preparation of cDNA, hybridisation, and scanning of the arrays were 
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performed according to the manufacturer's instructions. The arrays were scanned using 
the Affymetrix GeneArray scanner. Image analysis was performed with the Affymetrix 
GeneChip software.  We also performed a quality control test on the dataset using the R 
package ‘affyQCReport’ (17) and the results were favourable. 
 
Data 
 
The data from all 50 gene chips was normalised using the GCRMA method developed by 
(18).  The 50 donor lung samples were divided into two groups - those that developed 
PGD after transplantation (PGD positive) and those that did not (PGD negative). PGD 
was defined as T0 Grade III dysfunction according to International Society for Heart and 
Lung Transplantation criteria, that is, a ratio (referred to as the P/F ratio) of partial 
pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FiO2) less than 200 in 
the first arterial blood gas in the intensive care unit after transplantation (generally 4-6 
hours after actual reperfusion) (19).   Although definitions of PGD at later time points 
may more accurately reflect outcomes after transplantation, they may also be potentially 
affected by other postoperative factors such as overall fluid balance or presence of 
infection.   Sixteen samples were classified as PGD positive according to this definition 
and the remaining thirty-four were PGD negative.   
 
Transcripts Selection 
 
We then proceeded to the next step in our study - the identification of differentially 
expressed (DE) transcripts. The objective was to find a set of DE transcripts/probes that 
could be used as a molecular signature for the condition.  DE transcript extraction falls 
into two broad categories - wrapper methods and filter methods.  In wrapper transcript 
selection methods, the DE transcript identification phase is integrated with the 
classification phase. In filter methods, the DE transcript extraction phase is independent 
of the classification phase. In this study, we used two packages for the identification of 
DE transcripts - RankGene (20), and significance analysis of microarrays (SAM) (21). 
 
RankGene is a programme for analysing gene expression data, feature selection and 
ranking genes based on the predictive power of each gene/transcript to classify samples 
into functional or disease categories.  It supports eight different measures for quantifying 
a gene's ability to distinguish between classes.  For our analysis, we used the t-statistics 
measure of predictability.  The t-statistic value is a score for each gene’s ability to 
discriminate between the 2 classes.  RankGene ranks genes according to the decreasing 
order of the absolute value of the t-statistic for each gene.  The group of top genes from 
this ranked list is considered to be the most informative for distinguishing between the 
classes.  SAM is open-source software which identifies DE genes based on the change in 
gene expression relative to the standard deviation of repeated measurements (21). It uses 
the false discovery rate (FDR) and q-value method presented in (22) to select genes.  As 
microarrays result in the measurement of several thousand probes, the individual p-values 
are not a good measure of significance.  The q-value is used to adjust for multiple testing.   
It is analogous to the p-value and is corrected, through a permutation process, for the 
variability of the expression data. The q-value of a transcript is the FDR for the transcript 
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list that includes that transcript and all transcripts that are more significant.  SAM also 
provides the tail strength (TS) value which measures the deviation of each p-value from 
its expected value. Therefore, large positive TS values indicate evidence against the null 
hypothesis, i.e., there are more small p-values than one would expect by chance (23). 
 
We first ran RankGene on the complete set of probes.  Since we were interested in the 
most highly DE transcripts, we chose to take the top 100 transcripts from the ranked list 
for further analysis.  On this list of 100 DE transcripts, we applied SAM.  SAM displayed 
81 differentially expressed transcripts based on a FDR of 0% and a TS of 92.7%.  After 
averaging the values of and removing multiple probes mapping to the same gene name, 
23 upregulated and 42 downregulated transcripts were obtained.  These sets of up and 
down regulated transcripts were used for further analysis in Ingenuity Pathway Analysis 
software. 
 
Pathway analysis 
 
Ingenuity Pathway Analysis (IPA) (www.ingenuity.com) was used to perform pathway 
analysis on the two sets of DE transcripts - upregulated and downregulated, to identify 
networks of genes that are known to interact functionally. IPA uses the Ingenuity 
Pathways Knowledge Base (IPKB) which contains large amounts of individually 
modelled relationships between objects (e.g., genes, proteins and mRNAs) to 
dynamically generate significant biological/gene expression networks and pathways.  The 
identified DE transcripts from our analysis that are mapped onto the IPKB are called 
‘focus genes’. These are used as starting points for building the networks.  IPA consists 
of genes that have functions assigned to them and are in published literature.  First, IPA 
queries the IPKB for interactions between the focus genes and all other genes stored in 
IPKB and then generates a set of networks/pathways with a maximum of 35 genes.  A p 
value for each network is calculated according to the user's list of DE genes. This is 
accomplished by comparing the number of focus genes that are present in a given 
pathway, relative to the total number of occurrences of those genes in all pathways stored 
in IPKB.  The score of the network is shown as the negative logarithm of the p value, 
indicating the likelihood of the focus genes in a network being found together by random 
chance.  In our study, we further analysed networks that had a network score of 10 or 
higher. If genes do not have any known functions assigned to them, they do not become 
focus genes in IPA although they have a gene name. This network analysis is an 
exploratory in silico approach and does not necessarily indicate that the pathway or 
network actually exists. 
 
Support Vector Machines 
 
Originally developed by Vapnik (24), the support vector machine (SVM) is a statistical 
learning tool which has been extensively used for binary classification with great success.  
Ranging from classification of cancer (25) to determination of haemodialysis dosage 
(26), SVMs have proven to be an effective tool in a wide-range of applications. 
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SVM was used for the classification of patient samples into PGD positive or PGD 
negative categories.  The dataset consisted of 50 patient samples and 100 transcripts 
(ranked transcripts from RankGene). Following is the manner in which SVM was used.  
The dataset is divided into training and test (unseen by the classifier) sets. The test set is 
also the validation set because although the user knows the classes of the samples in the 
test set, the classifier does not see the samples in the test set while it is training. The SVM 
is trained on the training set. The classifier performance is measured by the prediction 
accuracy on the test set.  It is quite well known that the set of significant genes (SG) from 
a particular set of training data is very often very different from one chosen from a 
different set of training data.  Obtaining a SG set from the complete dataset (i.e. from all 
50 patient samples), leads to a selection bias. In order to avoid selection bias, an external 
cross-validation (CV) was performed i.e. the classifier performance was measured using 
only the set of genes (i.e. a subset of the 100 transcripts) obtained from the training set 
and not from the complete dataset of 50 patients. Ten fold CV was carried out rather than 
leave-one-out (LOO) CV, as the variability in the list of SG is much lower with 10 fold 
CV and this is what is preferred.  Results were averaged over 20 runs.   
 
 
 
Results and Discussion 
 
The definition of PGD used in this study was T0 Grade III PGD as described by the 
International Society for Heart and Lung Transplantation consensus statement on the 
definition of primary graft dysfunction (19).  In this statement, any time between 
immediately post-transplant (T0, ideally defined as arrival in the ICU, within 6 hours 
post-reperfusion) and 72 hours after transplantation  (T72) can be used to measure blood 
gases and define PGD.  Although definitions of PGD at later time points may more 
accurately reflect outcomes after transplantation, they may also be potentially affected by 
other postoperative factors such as overall fluid balance or presence of infection.  Our 
objective in this study was to identify biologic risk factors in donor lungs that may 
contribute to PGD and therefore we felt that this was most purely measured at T0, where 
lung function may most clearly reflect the status of the donor lung at the time of harvest.  
Furthermore, data from our institution suggests that PGD as early as T0 is associated with 
the development of bronchiolitis obliterans syndrome (chronic rejection) (27).  
 
The characteristics of the donor lungs are depicted in Table 1.  The operative factors and 
the outcome of patients with PGD versus those without are shown in Table 2 and Table 3, 
respectively.   Despite other studies correlating donor age and recipient diagnosis of PPH 
with PGD, we have not seen a significant correlation in our samples.  Although, 
cardiopulmonary bypass (CPB) seemed to be significant, it could also occur as a result of 
PGD rather than be a causative factor of PGD.   SAM analysis resulted in 81 
differentially expressed (DE) transcripts which resolved into 65 unique genes using 
DAVID (http://niaid.abcc.ncifcrf.gov/tools.jsp) at the time of writing this paper.  This list 
along with the fold change is presented in Table 4.  A flowchart depicting the sequence of 
analysis is shown in Figure 1.    
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Pathways and gene products involved in PGD: 
 
The upregulated transcripts were analysed using the Ingenuity Pathway Analysis (IPA) 
software.  There were 23 upregulated transcripts, of which 13 were focus genes.  Focus 
genes are the genes that map onto the Ingenuity Pathways Knowledge Base (IPKB).  The 
network generated from these genes is shown in Figure 2. 
 
Network 1 primarily centres on tumour protein p53 (TP53).  The focus genes are shown 
in shaded/solid shapes and more details on these nodes are given in the supplementary 
material (Table 1).  Figure 3 shows the location of the different gene products and the 
canonical pathways present in Network 1.  The legend for the network is shown in Figure 
7.  It is natural to expect many pathways related to apoptosis and cell signalling as over 
50% of the donor lungs (PGD positive and PGD negative) were involved in some kind of 
trauma.  Interestingly, a few transcripts identified are also cancer related genes. There is 
growing evidence of genetic parallels between lung development and several types of 
cancer (28, 29).  The authors of (30) have shown that Wnt signalling, cell cycle, and 
apoptosis pathways play important roles in lung development.  We also have noticed an 
increased presence of genes in these pathways in our study (Figure 3). 
 
Next, we analysed the 42 downregulated transcripts using IPA, and obtained 11 focus 
genes.  The network created from these 11 genes is shown in Figure 4.  Network 2 shows 
a lot of activity around beta-5 integrin (ITGB5) and GRB2-associated binding protein 2 
(GAB2).  The focus genes are shown in shaded/solid shapes and further description of 
these nodes are given in the supplementary material (Table 2).  Figure 5 shows the 
location of the different gene products and the canonical pathways present in Network 2.  
The legend for the network is shown in Figure 7.  We observe similar pathways, as the 
ones present in Network 1, in Network 2.  This is not unexpected since a pathway can 
consist of up and downregulated genes. 
 
Both the networks show the presence of nuclear factorKB (NFKB), stress-activated 
protein kinases NH2-terminal Jun kinase (SAPK/JNK) and p38 mitogen-activated protein 
kinase (MAPK) signalling pathways. NFKB plays a vital role in mediating immune and 
inflammatory responses, and apoptosis. It regulates the expression of a large number of 
genes. Many of the gene products regulated by NFKB in turn activate NFKB, such as 
vascular endothelial growth factor (VEGF), and receptor for advanced glycation end 
product (RAGE). Activation of NFKB involves the phosphorylation-induced, 
proteasome-mediated degradation of the inhibitory subunit - inhibitory protein KB.  This 
protein is phosphorylated by an upstream serine kinase, which, in turn is phosphorylated 
and activated by additional upstream serine kinases.  SAPK/JNK are members of the 
superfamily of MAP serine/threonine protein kinases.  This family also includes p38 
MAP kinases (p38 MAPK) and extracellular signal-related kinases (ERK) (31). 
JNK/SAPK and p38 MAPK are known as stress-activated kinases, and are responsive to 
numerous exogenous and endogenous stress-inducing stimuli, such as reactive oxygen 
species (ROS), oxidative stress, osmotic stress, proinflammatory cytokines, heat shock, 
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and ultraviolet irradiation. Oxidative stress is defined as a persistent imbalance between 
the production of highly reactive molecular species (primarily oxygen and nitrogen) and 
antioxidant defences, finally resulting in tissue damage.  There is evidence in literature 
that NF-KB, SAPK/JNK and p38 MAPK signalling pathways are stress-sensitive 
intracellular signalling systems, activation of which results in the increased expression of 
numerous gene products that cause cellular damage (32).   
 
Gene products associated with stress-activated pathways emerged from both our study as 
well as the study in the rat model for ischemia-reperfusion injury (16). As the 
experimental protocol, and animal model are different, one would not expect too much of 
an overlap.  As suggested by the recent articles in Nature Biotechnology by the 
MicroArray Quality Control (MAQC) project (33), it is better to focus on pathways and 
broad functional relationships, rather than on individual genes. They state that “even 
under the best circumstances, gene lists will still differ somewhat from person to person 
and place to place”.  In our work, we have observed a good deal of overlap in the 
functional categories/pathways of the identified transcripts. As not all animal model 
studies translate well into human analysis, our investigation takes the study performed by 
(16) a step further by performing the analysis on human samples and showing consensus. 
 
An exciting observation was that the metallothionein family of gene products was 
identified as being upregulated in the lungs that did not develop PGD.  In the work by 
Yamane et al (16), metallothionein levels of expression are much lower in the microarray 
when compared to most of the other genes considered significant. However, RT-PCR 
confirms that it does have an increased expression.  Hence, the rat study as well as ours 
does confirm the elevated expression of metallothionein. 
 
Metallothioneins (MT) are ubiquitous, low molecular weight, intracellular zinc-binding 
proteins with antioxidant properties.  MT consists of 3 isoforms – MT1, MT2 and MT3.  
We extracted the metallothionein 3 (MT3) pathway from Network 1 (see Figure 6).  
Although the exact mechanism by which MT3 operates is not well known, there are a few 
studies that have explained the possible roles of metallothionein, especially MT1 and 
MT2. A recent study has shown that metallothioneins have positive effects during the 
early phase of islet transplantation (34).  Another study has shown that the 
metallothionein gene is upregulated in wound margins particularly in regions of high 
mitotic activity (35). These observations reflect its role in promoting cell proliferation 
and re-epitheliation. Furthermore, selected growth factors may modulate metallothionein 
gene expression and hence, the ability of cells to proliferate (35). As can be seen from 
Figure 6, MT3 is connected to NF-KB1.  In human fibroblasts, NFKB protein consisting 
of p50 [NFKB1] and of p65 v-rel reticuloendotheliosis viral oncogene homolog A 
(RELA) increases expression of human MT3 mRNA.  There is also an indirect 
relationship between MT3 and epidermal growth factor (EGF).  EGF is involved in EGF 
signalling, ephrin receptor signalling, neuregulin signalling, and NFKB signalling. EGF's 
role in the cell is proliferation, migration, mitogenesis, apoptosis, growth, chemotaxis, 
transformation, stimulation, S phase, and differentiation.  Several other papers have also 
shown that metallothionein positively regulates the cellular level and activity of NF-KB 
(36, 37). Recent work by St. Croix et al (38), has also shown the protective role of 
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metallothionein in acute lung injury. Cells deficient in MT1 and MT2 have shown 
increased sensitivity to apoptosis (39).  Other work suggests that under inflammatory 
conditions, MT supports beneficial movement of leukocytes to the inflammation site 
(40).  In vitro experiments have shown that modest increase in MT levels still provides 
protection against oxidative stress (41).  All this research on MT suggests that it is a 
valuable gene and should be analysed in extensive detail in the context of PGD.  
Furthermore, whether the MT3 isoform has the same properties as MT1 and MT2 needs 
to be determined.  The overexpression of metallothionein 3 may protect the lung graft 
from PGD.  We feel that this is one of the most important insights into the mechanism of 
PGD. 
 
Classification of donor lungs using SVM: 
 
The set of 100 ranked transcripts, obtained using RankGene, was used for the 
classification of donor lungs into PGD positive and PGD negative classes by SVM. The 
classification accuracy of SVM in differentiating the two classes was 70%. This indicates 
that this set of transcripts has enough information to distinguish unsuitable and suitable 
donor lungs. 
 
The SVM did better at identifying the suitable lungs (i.e. low false negative). Considering 
that the motivation behind using machine learning for the selection of suitable donor 
lungs was to detect those that otherwise would have been discarded, this observation is 
promising. The unsuitable donor lungs were more often misclassified and this can be 
attributed to the fact that there were very few unsuitable donor lungs in the dataset (16 
unsuitable lungs versus 34 suitable lungs) and subsequently, an even smaller number in 
the training set. Furthermore, our dataset had been pre-selected by physicians based on 
clinical criteria.  Hence, the dataset did not have truly unsuitable donor lungs, i.e., lungs 
considered unsuitable by clinical criteria.  Obviously, certain lungs that passed the 
selection criteria developed PGD. In essence, these were lungs that seemed to be good by 
the current clinical criteria.  Hence, the gene expression patterns of the unsuitable donor 
lungs are very similar to the patterns of suitable lungs.  In fact, when the gene expression 
values of the DE transcripts were compared between PGD positive and PGD negative 
lungs, the difference was marginal.  These observations are not surprising as both sets of 
lungs were considered suitable by clinical criteria, and therefore the difference between 
them would be very subtle. 
 
The SVM had difficulty in recognising some unsuitable donor lungs as it was not being 
trained on the gene expression pattern of a large number of unsuitable donor lungs, or, for 
that matter, on a large number of truly unsuitable donor lungs. Given the fact that we had 
only 50 samples, in which we did not have truly unsuitable lungs, the classification 
performance is good. Increasing the sample size in both categories would lead to a more 
accurate and possibly larger set of DE transcript involved in PGD, as well as improved 
classification results. 
 
As the differences at the macroscopic level between PGD positive and PGD negative 
donor lungs are minimised after employing the clinical selection criteria, gene expression 
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profiling would help in amplifying whatever small differences there may be.  SVMs are 
capable of using these marginal differences to identify suitable and unsuitable donor 
lungs.  This is where machine learning plays a valuable role - assisting physicians and not 
necessarily overruling them.  Hence, machine learning methods, such as SVMs, can be 
used in conjunction with clinical criteria to identify unsuitable donor lungs, thereby 
further decreasing the chances of using donor lungs that would develop PGD.  Due to the 
limited dataset, it would be advantageous to have a larger dataset for further validation. 
 
The study design affects the kind of questions that can be posed as well as the quality of 
answers.  As this was a pilot study to test the feasibility of the approaches, we restricted it 
to only a few samples.  Furthermore, we did not have enough tissue material to perform 
RT-PCR to validate the microarray results.  We hope that this research would motivate 
and warrant the need for a larger study with more sophisticated statistical methods as well 
as microarray validation tools.  Moreover, an animal model would allow for more 
samples to be taken at different time points which would further strengthen the study.   
An interesting strategy would be to perform a random sampling of different regions of the 
lung and subject it to microarray analysis.  This was not done in this study due to three 
reasons – 1) taking multiple samples from a donor lung when the primary objective is 
transplantation is difficult to justify; 2)  taking samples from different regions of the lung 
necessitates the need for a larger sample set in order to reduce variance and increase 
statistical power and finally 3) it was convenient to take a biopsy from the lingula or 
anterior right middle lobe as opposed to other regions, without compromising the amount 
of time the lung is kept without cold flushing.   Due to the limited number of samples, we 
could not perform an external validation and resorted to a 10-fold cross validation, which 
is normal in many cases where SVM has been used for classification in a clinical study.  
Furthermore, in order to improve the classification accuracy, it would be necessary to 
include lungs in the training set that have been rejected by the clinical criteria.  Although 
we obtained 23 upregulated and 42 downregulated transcripts, only 13 of the 23 and 11 of 
the 42 transcripts became focus genes in IPA.  This indicates that the majority of the 
transcripts do not have any specific function assigned to them as yet.  Further research 
into the functions of these transcripts will also provide some insight into their role in 
PGD.   
 
 
 
Conclusion  
 
The incorporation of biological information into donor lung evaluation, based on studies 
such as this one, may deem many of the excluded organs as suitable for transplantation, 
directly impacting the mortality of patients on the lung transplant waiting list.  Studies 
show that 15-25% of patients develop clinically significant primary graft dysfunction 
(PGD) after lung transplantation. PGD is the single most significant factor in determining 
perioperative morbidity and mortality and has a devastating impact on outcome following 
lung transplantation. It is the primary factor determining duration of mechanical 
ventilatory support and length of ICU and hospital stay following lung transplantation. 
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Perioperative mortality rates for those with clinically significant PGD are as high as 40-
60%. One year survival rates fall from 69% to 40% and 2-year rates from 66% to 27% in 
those who suffer significant PGD. Furthermore, those that survive complications of PGD 
endure lengthy hospitalisation periods and a protracted and often compromised recovery, 
evidenced by inferior exercise tolerance and pulmonary function testing and the inability 
to achieve independent lifestyles.  Moreover, PGD is now being identified as a risk factor 
for acute and chronic rejection. 
 
In this study, gene expression profiling of donor lung samples was used to determine 
gene products that are associated with the development of PGD after transplantation. It 
also resulted in analysing possibly relevant pathways involved in PGD.  When biological 
markers were used to differentiate between PGD positive and PGD negative lungs, good 
classification accuracy was achieved.  The incorporation of biological markers into donor 
organ evaluation will have a significant impact on outcomes after lung transplantation, by 
potentially expanding the donor pool of organs selected for transplantation and by 
identifying lungs at risk for the development of PGD post-transplant, which would allow 
pre-treatment of these high risk organs or matching of these organs to relatively lower 
risk recipients.  Further identification and elucidation of genetic markers in donor lungs 
associated with PGD could have a significant impact on lowering the incidence and 
preventing the morbidity and mortality of PGD after lung transplantation.  Our results 
indicate that we have successfully achieved both our objectives. 
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Table 2: Description of the downregulated transcripts from our DE list present in Network 2. 
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TABLES 
 
TABLE 1: Clinical Donor Characteristics 
Characteristics PGD (n=16) No PGD (n=34) p value 
Age (years) 26.6 ± 8.9 24.0 ± 9.8 0.53 
PaO2 406.7 ± 80.5 449.7 ± 80.0 0.17 
Smoking history (years) 1.5 ± 2.07 2.9 ± 6.32 0.59 
Gender 71% M, 29% F 83% M, 17% F 0.78 
Cause of death 57% Trauma, 43% non-Trauma 75% Trauma, 25% non-Trauma 0.66 
Marginal donors 1 4 0.99 
 
 
TABLE 2: Operative factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3: Outcomes of patients with and without PGD 
Outcome PGD (n=16) No PGD (n=34) p value 
Days on ventilator 9.7 ± 11.7 2.0 ± 3.7 0.01 
ICU stay (days) 11.3 ± 12.6 2.9 ± 3.6 0.006 
Total length of stay (days) 20.3 ± 13.0 13.4 ± 8.1 0.09 
Perioperative mortality 28.5% 0% 0.02 
 
 
 
 
 
 
 
 
Factors PGD (n=16) No PGD (n=34) p value 
Recipient diagnosis 32% COPD, 25% CF, 
43% other 
35% COPD, 32.5% CF, 
32.5% other 
0.98 
Recipients with PPH 2 1 0.24 
1st lung ischemic time 
(min) 
208.0 ± 44.0 240.0 ± 51.0 0.18 
2nd lung ischemic time 
(min) 
330.0 ± 72.0 321.0 ± 51.0 0.69 
Cardiopulmonary bypass 
(CPB) 
72% 17% 0.02 
 
 16 
TABLE 4: List of 81 differentially expressed transcripts output by SAM.  There are 23 
upregulated and 42 downregulated genes. 
 
UP-regulated in PGD 
negative lungs  
 
REFSEQ_MRNA Gene Name 
Fold 
Change 
NM_005633 SON OF SEVENLESS HOMOLOG 1 (DROSOPHILA) 2.2183831 
NM_000492 
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, ATP-BINDING 
CASSETTE (SUB-FAMILY C, MEMBER 7) 1.7822446 
NM_003645 FATTY-ACID-COENZYME A LIGASE, VERY LONG-CHAIN 1 1.7679424 
NM_005573 LAMIN B1 1.6928441 
NM_005502 ATP-BINDING CASSETTE, SUB-FAMILY A (ABC1), MEMBER 1 1.6240539 
NM_017613 DOWNSTREAM NEIGHBOR OF SON 1.5424873 
NM_019841 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 5 1.5196761 
NM_017760 LEUCINE ZIPPER PROTEIN 5 1.5172142 
NM_018365 MEIOSIS-SPECIFIC NUCLEAR STRUCTURAL 1 1.5161006 
NM_183419, NM_015435 RING FINGER PROTEIN 19 1.4642686 
NM_015024 EXPORTIN 7 1.4545849 
XM_938545 SIMILAR TO FORMIN-BINDING PROTEIN 3 (FORMIN-BINDING PROTEIN 11) (FBP 11) 1.3552737 
NM_017654 STERILE ALPHA MOTIF DOMAIN CONTAINING 9 1.3251204 
NM_016265 ZINC FINGER PROTEIN 12 1.2960459 
NM_005531 INTERFERON, GAMMA-INDUCIBLE PROTEIN 16 1.2918867 
NM_007358 METAL RESPONSE ELEMENT BINDING TRANSCRIPTION FACTOR 2 1.2824896 
NM_005954 METALLOTHIONEIN 3 (GROWTH INHIBITORY FACTOR (NEUROTROPHIC)) 1.2808244 
NM_015205, NM_032189 ATPASE, CLASS VI, TYPE 11A 1.2417599 
NM_007118 TRIPLE FUNCTIONAL DOMAIN (PTPRF INTERACTING) 1.1514956 
NM_001004420, 
NM_001004419, NM_013269 C-TYPE LECTIN DOMAIN FAMILY 2, MEMBER D 1.1469583 
NM_181657 LEUKOTRIENE B4 RECEPTOR 1.1067929 
NM_014229 
SOLUTE CARRIER FAMILY 6 (NEUROTRANSMITTER TRANSPORTER, GABA), 
MEMBER 11 1.0890867 
NM_201279, NM_003872, 
NM_201266 NEUROPILIN 2 1.0625556 
   
Down-regulated in PGD 
negative lungs 
  
REFSEQ_MRNA Gene Name 
Fold 
Change 
NM_024917 CHROMOSOME X OPEN READING FRAME 34 2.3873841 
NM_024508 ZINC FINGER, BED-TYPE CONTAINING 2 2.0313459 
NM_022460 HS1-BINDING PROTEIN 3 1.6525671 
NM_178312, NM_178311, 
NM_080920 GAMMA-GLUTAMYLTRANSFERASE-LIKE ACTIVITY 4 1.5240059 
NM_198544 CORTISTATIN 1.5027289 
NM_014241 
PROTEIN TYROSINE PHOSPHATASE-LIKE (PROLINE INSTEAD OF CATALYTIC 
ARGININE), MEMBER A 1.4121977 
NM_079837, NM_017869 BTG3 ASSOCIATED NUCLEAR PROTEIN 1.3943394 
NM_025124 HYPOTHETICAL PROTEIN FLJ21749 1.3593494 
NM_001017962, NM_000917 
PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE 4-DIOXYGENASE (PROLINE 4-
HYDROXYLASE), ALPHA POLYPEPTIDE I 1.3539779 
NM_022337 RAB38, MEMBER RAS ONCOGENE FAMILY 1.3356873 
NM_002035 FOLLICULAR LYMPHOMA VARIANT TRANSLOCATION 1 1.3315413 
NM_024956 TRANSMEMBRANE PROTEIN 62 1.3201902 
NM_003562 
SOLUTE CARRIER FAMILY 25 (MITOCHONDRIAL CARRIER; OXOGLUTARATE 
CARRIER), MEMBER 11 1.3193721 
NM_007001 SOLUTE CARRIER FAMILY 35, MEMBER D2 1.3140864 
XM_929985 SIMILAR TO LARGE SUBUNIT RIBOSOMAL PROTEIN L36A 1.3078617 
NM_021029 RIBOSOMAL PROTEIN L36A 1.3078617 
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NM_019040 ELONGATION PROTEIN 4 HOMOLOG (S. CEREVISIAE) 1.2951361 
NM_015654 N-ACETYLTRANSFERASE 9 1.2935561 
NM_007069 HRAS-LIKE SUPPRESSOR 3 1.2878168 
XM_937648 
SIMILAR TO ALVEOLAR SOFT PART SARCOMA CHROMOSOME REGION, 
CANDIDATE 1 1.2864441 
NM_153741, NM_018973 DOLICHYL-PHOSPHATE MANNOSYLTRANSFERASE POLYPEPTIDE 3 1.2849801 
NM_014320 HEME BINDING PROTEIN 2 1.2791263 
NM_006476 ATP SYNTHASE, H+ TRANSPORTING, MITOCHONDRIAL F0 COMPLEX, SUBUNIT G 1.2710706 
NM_002513 NON-METASTATIC CELLS 3, PROTEIN EXPRESSED IN 1.2675264 
NM_018158 SOLUTE CARRIER FAMILY 4 (ANION EXCHANGER), MEMBER 1, ADAPTOR PROTEIN 1.2606948 
NM_002213 INTEGRIN, BETA 5 1.2579474 
NM_005865 PROTEASE, SERINE, 16 (THYMUS) 1.2495258 
NM_020385 REX4, RNA EXONUCLEASE 4 HOMOLOG (S. CEREVISIAE) 1.2404477 
NM_015958 DPH5 HOMOLOG (S. CEREVISIAE) 1.2402215 
NM_021824 NIF3 NGG1 INTERACTING FACTOR 3-LIKE 1 (S. POMBE) 1.2392898 
NM_014173, NM_001033549 HSPC142 PROTEIN 1.2375188 
NM_213622, NM_201647, 
NM_006463 STAM BINDING PROTEIN 1.2360276 
NM_207356 CHROMOSOME 1 OPEN READING FRAME 174 1.2286265 
NM_016142 HYDROXYSTEROID (17-BETA) DEHYDROGENASE 12 1.2277373 
NM_016080 CHROMOSOME 17 OPEN READING FRAME 25 1.2263789 
NM_080491, NM_012296 GRB2-ASSOCIATED BINDING PROTEIN 2 1.2246286 
NM_032900 RHO GTPASE ACTIVATING PROTEIN 19 1.2229376 
NM_004699 FAMILY WITH SEQUENCE SIMILARITY 50, MEMBER A 1.2086274 
NM_003060 SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 5 1.1931567 
NM_014300 SEC11-LIKE 1 (S. CEREVISIAE) 1.1914145 
NM_024766 CHROMOSOME 2 OPEN READING FRAME 34 1.1822266 
NM_001004 RIBOSOMAL PROTEIN, LARGE, P2 1.1529057 
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FIGURE LEGENDS 
 
FIGURE 1: Sequence of analysis undertaken in this study.  Gene expression profiling was conducted on 50 
lung samples.  The transcripts were ranked using RankGene in descending order of their t-statistic and the 
top 100 were selected for further analysis.  This set of 100 transcripts was used for classification by SVM 
and resulted in an accuracy of 70%.  The set of 100 transcripts was also analysed using SAM to determine 
up and down regulated transcripts.  SAM output 81 differentially expressed transcripts.  After averaging the 
values of and removing multiple probes mapping to the same gene name, 23 upregulated and 42 
downregulated transcripts were obtained.  Of the 23 upregulated transcripts, 13 became focus genes in IPA 
and of the 42 downregulated, 11 were focus genes in IPA.   
 
FIGURE 2: Network 1 - upregulated genes in PGD.  This network primarily centres on tumour protein p53 
(TP53).  The focus genes are shown in shaded/solid shapes.  Further details on the focus genes are 
provided in Table 4. The legend for this figure is Figure 7. 
 
FIGURE 3: Network 1 with canonical pathways overlaid.  The focus genes are shown in shaded/solid 
shapes.  The location of the gene products is also indicated.  Further details on the focus genes are provided 
in Table 4.  The legend for the figure is Figure 7. 
 
FIGURE 4: Network 2 - downregulated genes in PGD.  This network shows a lot of activity around beta-5 
integrin (ITGB5) and GRB2-associated binding protein 2 (GAB2).  The focus genes are shown in 
shaded/solid shapes.  Further details on the focus genes are provided in Table 5. The legend for this 
figure is Figure 7. 
 
FIGURE 5: Network 2 with the canonical pathways overlaid.  The focus genes are shown in 
shaded/solid shapes. The location of the different gene products is also depicted. Further details on the 
focus genes are provided in Table 5.  The legend for this figure is Figure 7. 
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FIGURE 6: Network 3 - Metallothionein pathway.  In human fibroblasts, NFKB protein consisting of p50 
[NFKB1] and of p65 v-rel reticuloendotheliosis viral oncogene homolog A (RELA) increases expression of 
human MT3 mRNA.  The overexpression of metallothionein may protect the lung graft from PGD.  The 
legend for this figure is Figure 7. 
 
FIGURE 7: Network Legend (a) Key for nodes in the network, (b) Key for edges in the network, (c) Key 
for edge labels in the network 
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